Vaxxinity Shares Plummet Amid Extreme Volatility

Vaxxinity’s stock is experiencing a period of intense pressure, having collapsed to record lows while displaying extraordinary price swings. The biotech company’s shares are now navigating highly uncertain territory following its delisting from the Nasdaq exchange and the termination of its mandatory SEC reporting obligations.

In a significant move during April 2024, Vaxxinity voluntarily withdrew from the regulated marketplace. The company formally requested delisting from Nasdaq, citing what it described as an “abusive relationship” with public markets. This decision carries substantial implications: Vaxxinity no longer must file quarterly earnings, annual financial statements, or any other mandatory disclosures with the Securities and Exchange Commission. With the stock now trading Read more...